Organogenesis Holdings Inc.
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company that develops, manufactures and sells products for advanced wound care and surgical and sports medicine. Its products address chronic and acute wounds, including venous leg ulcers and diabetic foot ulcers, as well as soft-tissue repair and… From the company’s description.
Over the twelve months to Sep 30, 2026, Organogenesis Holdings Inc. reported revenue of $352.05M, down 24.3% from a year earlier, and a net loss of $135.35M. Its operating margin was −24.5%, and operations generated $10.30M in cash. In fiscal 2025, it reported revenue of $564.17M, up 17.0% from fiscal 2024, and net income of $37.03M.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What Organogenesis Holdings Inc. does
In the company’s own words
Organogenesis Holdings Inc. (Nasdaq: ORGO) is a regenerative medicine company that develops, manufactures and sells products for advanced wound care and surgical and sports medicine. Its products address chronic and acute wounds, including venous leg ulcers and diabetic foot ulcers, as well as soft-tissue repair and tendon and ligament injuries. Customers include hospitals, wound care centers, government facilities, ambulatory surgery centers and physician offices. The company serves two markets: Advanced Wound Care and Surgical & Sports Medicine. Its portfolio includes Apligraf and Dermagraft, bioengineered skin and dermal substitutes; PuraPly antimicrobial and collagen products; and placental-tissue products such as Affinity, Novachor, NuShield and CYGNUS. ReNu, a cryopreserved amniotic suspension being developed for knee osteoarthritis, is in the company’s pipeline. Organogenesis sells primarily in the United States through direct sales representatives and independent agencies; at December 31, 2025, it had 224 direct sales representatives and approximately 175 independent agencies. The company acquired NuTech Medical and its placental-based products in 2017.
Company details
- Sector
- Health Care
- Industry (SIC)
- Pharmaceutical Preparations
- Headquarters
- CANTON, MA
- Fiscal year end
- December
- CIK
- 1661181
- SIC
- 2834
Financial performance, year by year
Fiscal 2016–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns Organogenesis Holdings Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · Organogenesis Holdings Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do Organogenesis Holdings Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of Organogenesis Holdings Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in Organogenesis Holdings Inc.'s last four quarterly filings that the numbers alone won't show?”